Adolore BioTherapeutics Announces FDA Orphan Drug Designation for its Kv7-activating rdHSV-CA8* Therapy in the Treatment of Erythromelalgia

Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due to ...

The $44 Billion Rehab Industry Faces Disruption: Virtual Outpatient Programs Deliver Superior Outcomes at Fraction of Cost

New Telehealth Model Combines Weekly Therapy with Daily Professional Coaching, Allowing Clients to Maintain Work and ...